724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)

• Aranzazu Manzano,
• Omid Hamid,
• Emiliano Calvo,
• Marc S Ernstoff,
• Anthony J Olszanski,
• John Wrangle,
• Anthony F Shields,
• Stephen V Liu,
• Sarina A Piha-Paul,
• Trisha M Wise-Draper,
• Yangchun Du,
• Justin A Call,
• Shwetha Asha,
• Ralph Boccia,
• Angela Tatiana Alistar,
• Carlos Mayo,
• Leah Rider

Affiliations

Aranzazu Manzano

11UTEC Hospital Clínico San Carlos, Madrid, Spain

Omid Hamid

1The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA

Emiliano Calvo

START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain

Marc S Ernstoff

14Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Anthony J Olszanski

2Fox Chase Cancer Center, Philadelphia, PA, USA

John Wrangle

9Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA

Anthony F Shields

10Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, MI, USA

Stephen V Liu

3Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA

Sarina A Piha-Paul

2Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Trisha M Wise-Draper

14Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH, USA

Yangchun Du

13Alkermes, Inc., Waltham, MA, USA

Justin A Call

5Utah Cancer Specialists, West Valley City, UT, USA

Shwetha Asha

13Alkermes, Inc., Waltham, MA, USA

Ralph Boccia

4The Center for Cancer and Blood Disorders, Bethesda, MD, USA

Angela Tatiana Alistar

7Atlantic Health System, Atlantic Medical Group, Morristown, NJ, USA

Carlos Mayo

13Alkermes, Inc., Waltham, MA, USA

Leah Rider

13Alkermes, Inc., Waltham, MA, USA